{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:48:35Z","timestamp":1787806115161,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T00:00:00Z","timestamp":1488585600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf - Case Rep"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40800-017-0048-x","type":"journal-article","created":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T01:04:45Z","timestamp":1488589485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Psychomotor Agitation Following Treatment with Hydroxychloroquine"],"prefix":"10.1007","volume":"4","author":[{"given":"Ciro","family":"Manzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Gareri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,4]]},"reference":[{"issue":"1A","key":"48_CR1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0002-9343(83)91269-X","volume":"75","author":"AH McKenzie","year":"1983","unstructured":"McKenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;75(1A):40\u20135.","journal-title":"Am J Med."},{"key":"48_CR2","unstructured":"Rynes RI. Antimalarials. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Philadelphia: Saunders Company; 2001. p. 864\u20135."},{"key":"48_CR3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1601-5215.2011.00575.x","volume":"23","author":"WH Hsu","year":"2011","unstructured":"Hsu WH, Chiu NY, Huang SS. Hydroxychloroquine-induced acute psychosis in a systemic lupus erythematosus female. Acta Neuropsychiatrica. 2011;23:318\u20139.","journal-title":"Acta Neuropsychiatrica."},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.5694\/j.1326-5377.1962.tb20626.x","volume":"49","author":"JF Drew","year":"1962","unstructured":"Drew JF. Concerning the side effects of antimalarial drugs used in the extended treatment of rheumatic diseases. Med J Aust. 1962;49:618\u201320.","journal-title":"Med J Aust."},{"issue":"10","key":"48_CR5","first-page":"2025","volume":"32","author":"F Tubach","year":"2005","unstructured":"Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. J Rheumatol. 2005;32(10):2025\u20139.","journal-title":"J Rheumatol."},{"key":"48_CR6","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.","edition":"5"},{"issue":"2","key":"48_CR7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther."},{"issue":"7","key":"48_CR8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archpsyc.1983.01790060110016","volume":"40","author":"MF Folstein","year":"1983","unstructured":"Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry. 1983;40(7):812.","journal-title":"Arch Gen Psychiatry."},{"issue":"3","key":"48_CR9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1468-1331.1996.tb00423.x","volume":"3","author":"E Magni","year":"1996","unstructured":"Magni E, Binetti G, Bianchetti A, et al. Mini-Mental State Examination: a normative study in Italian elderly population. Eur J Neurol. 1996;3(3):198\u2013202.","journal-title":"Eur J Neurol."},{"key":"48_CR10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-7643-7726-7_5","volume-title":"Antirheumatic therapy: actions and outcomes","author":"B Bothwell","year":"2005","unstructured":"Bothwell B, Furst DE. Hydroxychloroquine. In: Day RO, Furst DE, editors. Antirheumatic therapy: actions and outcomes. Basel: Piet L.C.M. van Riel and Barry Bresnihan; 2005. p. 81\u201392."},{"issue":"3","key":"48_CR11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/33.3.235","volume":"33","author":"AJ McLachlan","year":"1994","unstructured":"McLachlan AJ, Tett SE, Cutler DJ, Day RO. Bioavaliability of hydroxychloroquine tablets in patients with rheumatoid arthritis. Br J Rheumatol. 1994;33(3):235\u20139.","journal-title":"Br J Rheumatol."},{"key":"48_CR12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0950-3579(05)80004-4","volume":"4","author":"S Tett","year":"1990","unstructured":"Tett S, Cutler D, Day R. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol. 1990;4:467\u201389.","journal-title":"Baillieres Clin Rheumatol."},{"key":"48_CR13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","volume":"46","author":"T Munster","year":"2002","unstructured":"Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460\u20139.","journal-title":"Arthritis Rheum."},{"key":"48_CR14","unstructured":"Giacomello A. Antimalarici di sintesi derivati della 4-aminochinolina. In: D\u2019Elia S, D\u2019Erasmo E, Giacomello A, et al, editors. Farmacologia clinica reumatologica. Milan: Masson ed.; 1987. p. 98\u20139."},{"key":"48_CR15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"SE Tett","year":"1989","unstructured":"Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771\u20139.","journal-title":"Br J Clin Pharmacol."},{"key":"48_CR16","first-page":"278","volume":"23","author":"SJ Katz","year":"2011","unstructured":"Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: reappreciation and insights into new mechanisms of action. Curr Eye Res. 2011;23:278\u201381.","journal-title":"Curr Eye Res."},{"key":"48_CR17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF02976712","volume":"26","author":"KA Kim","year":"2003","unstructured":"Kim KA, Park JY, Lee SJ, Lim S. Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003;26:631\u20137.","journal-title":"Arch Pharm Res."},{"key":"48_CR18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.psym.2013.06.017","volume":"55","author":"P Das","year":"2014","unstructured":"Das P, Rai A, Chopra A, Philbrick K. Psychosis likely induced by hydropxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. Psychosomatics. 2014;55:409\u201313.","journal-title":"Psychosomatics."},{"key":"48_CR19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/bmj.282.6268.974","volume":"282","author":"MD Rawlins","year":"1981","unstructured":"Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ. 1981;282:974\u20136.","journal-title":"BMJ."},{"key":"48_CR20","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/ggi.12490","volume":"15","author":"YT Kwak","year":"2015","unstructured":"Kwak YT, Yang Y, Park SY. Chloroquine-associated psychosis mimicking very late-onset schizophrenia: case report. Geriatr Gerontol. 2015;15:1096\u20137.","journal-title":"Geriatr Gerontol."},{"key":"48_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40800-016-0030-z","volume":"3","author":"J Livezey","year":"2016","unstructured":"Livezey J, Oliver T, Cantilena L. Prolonged neuropsychiatric symptoms in a military service member exposed to mefloquine. Drug Saf Case Rep. 2016;3:7.","journal-title":"Drug Saf Case Rep."},{"key":"48_CR22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1475-2875-5-74","volume":"5","author":"TM Tran","year":"2006","unstructured":"Tran TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malaria J. 2006;5:74.","journal-title":"Malaria J."},{"key":"48_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00004714-198202000-00005","volume":"2","author":"MI Good","year":"1982","unstructured":"Good MI, Shader RI. Lethality and behavioral side effects of chloroquine. J Clin Psychopharmacol. 1982;2:40\u20137.","journal-title":"J Clin Psychopharmacol."},{"issue":"6","key":"48_CR24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ccr3.238","volume":"3","author":"NM Maxwell","year":"2015","unstructured":"Maxwell NM, Nevin RL, Stahl S, et al. Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy. Clin Case Rep. 2015;3(6):379\u201387.","journal-title":"Clin Case Rep."},{"issue":"5","key":"48_CR25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0190-9622(85)70109-0","volume":"12","author":"WQ Ward","year":"1985","unstructured":"Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol. 1985;12(5):863\u20135.","journal-title":"J Am Acad Dermatol."},{"key":"48_CR26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/0961203314558863","volume":"24","author":"JA Gonzales-Nieto","year":"2015","unstructured":"Gonzales-Nieto JA, Costa-Juan E. Psychiatric symptoms induced by hudroxychloroquine. Lupus. 2015;24:339\u201340.","journal-title":"Lupus."},{"issue":"12","key":"48_CR27","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.autrev.2015.07.015","volume":"14","author":"AF Joaquim","year":"2015","unstructured":"Joaquim AF, Appenzeller S. Neuropsychiatric manifestations in rheumatoid arthritis. Autoimmun Rev. 2015;14(12):1116\u201322.","journal-title":"Autoimmun Rev."}],"container-title":["Drug Safety - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40800-017-0048-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-017-0048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-017-0048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T10:20:09Z","timestamp":1601720409000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40800-017-0048-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s40800-017-0048-x","relation":{},"ISSN":["2199-1162","2198-977X"],"issn-type":[{"value":"2199-1162","type":"print"},{"value":"2198-977X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,4]]},"article-number":"6"}}